176 related articles for article (PubMed ID: 38423601)
41. BAP1 protein is a progression factor in malignant pleural mesothelioma.
Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
[TBL] [Abstract][Full Text] [Related]
42. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
Tolani B; Acevedo LA; Hoang NT; He B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
[TBL] [Abstract][Full Text] [Related]
43. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
44. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.
Tallet A; Nault JC; Renier A; Hysi I; Galateau-Sallé F; Cazes A; Copin MC; Hofman P; Andujar P; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Oncogene; 2014 Jul; 33(28):3748-52. PubMed ID: 23975423
[TBL] [Abstract][Full Text] [Related]
45. Co-occurring Mutations of Tumor Suppressor Genes,
Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
[No Abstract] [Full Text] [Related]
46. Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.
Plönes T; Fischer M; Höhne K; Sato H; Müller-Quernheim J; Zissel G
Pathol Oncol Res; 2017 Oct; 23(4):723-730. PubMed ID: 28054314
[TBL] [Abstract][Full Text] [Related]
47. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma.
Elshazley M; Sato M; Hase T; Yamashita R; Yoshida K; Toyokuni S; Ishiguro F; Osada H; Sekido Y; Yokoi K; Usami N; Shames DS; Kondo M; Gazdar AF; Minna JD; Hasegawa Y
Int J Cancer; 2012 Dec; 131(12):2820-31. PubMed ID: 22510946
[TBL] [Abstract][Full Text] [Related]
48. Wnt2 as a new therapeutic target in malignant pleural mesothelioma.
Mazieres J; You L; He B; Xu Z; Twogood S; Lee AY; Reguart N; Batra S; Mikami I; Jablons DM
Int J Cancer; 2005 Nov; 117(2):326-32. PubMed ID: 15900580
[TBL] [Abstract][Full Text] [Related]
49. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
[TBL] [Abstract][Full Text] [Related]
50. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
[TBL] [Abstract][Full Text] [Related]
51. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
Usami N; Fukui T; Kondo M; Taniguchi T; Yokoyama T; Mori S; Yokoi K; Horio Y; Shimokata K; Sekido Y; Hida T
Cancer Sci; 2006 May; 97(5):387-94. PubMed ID: 16630136
[TBL] [Abstract][Full Text] [Related]
52. Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment.
Sculco M; La Vecchia M; Aspesi A; Pinton G; Clavenna MG; Casalone E; Allione A; Grosso F; Libener R; Muzio A; Rena O; Baietto G; Parini S; Boldorini R; Giachino D; Papotti M; Scagliotti GV; Migliore E; Mirabelli D; Moro L; Magnani C; Ferrante D; Matullo G; Dianzani I
Eur J Cancer; 2022 Mar; 163():44-54. PubMed ID: 35032816
[TBL] [Abstract][Full Text] [Related]
53. Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Huang J; Tabata S; Kakiuchi S; The Van T; Goto H; Hanibuchi M; Nishioka Y
Oncotarget; 2013 Aug; 4(8):1172-84. PubMed ID: 23896451
[TBL] [Abstract][Full Text] [Related]
54. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
55. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.
Bahnassy AA; Zekri AR; Abou-Bakr AA; El-Deftar MM; El-Bastawisy A; Sakr MA; El-Sherif GM; Gaafar RM
Exp Mol Pathol; 2012 Aug; 93(1):154-61. PubMed ID: 22504106
[TBL] [Abstract][Full Text] [Related]
56. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
[TBL] [Abstract][Full Text] [Related]
57. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
58. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
[TBL] [Abstract][Full Text] [Related]
59. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
Sato H; Soh J; Aoe K; Fujimoto N; Tanaka S; Namba K; Torigoe H; Shien K; Yamamoto H; Tomida S; Tao H; Okabe K; Kishimoto T; Toyooka S
Int J Oncol; 2019 Jun; 54(6):2139-2148. PubMed ID: 30942424
[TBL] [Abstract][Full Text] [Related]
60. Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.
Kato T; Lee D; Wu L; Patel P; Young AJ; Wada H; Hu HP; Ujiie H; Kaji M; Kano S; Matsuge S; Domen H; Kaga K; Matsui Y; Kanno H; Hatanaka Y; Hatanaka KC; Matsuno Y; de Perrot M; Yasufuku K
Int J Oncol; 2016 Aug; 49(2):448-56. PubMed ID: 27279560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
